OncologyTube.com is the first and only free video sharing website dedicated to helping oncology professionals spread knowledge about cancer research through video, audio and other multimedia.
    • OncologyTube

      Site: OncologyTube

    • Products & Pricing
      • Banner Advertising Plans
      • Pre-Roll Advertising
      • Create a Video Release (VR)
      • Boost Earned Media Only $60
      • Create A Deep Dive Conversation
      • Portuguese
      • Spanish
      • Italian
      • Greek (Greece)
      • Sinhala
      • Polish
      • Arabic (Saudi Arabia)
      • Swedish (Sweden)
      • Portuguese (Brazil)
      • Hindi (India)
      • English (Australia)
      • Hebrew (Israel)
      • Czech
      • Chinese
      • Turkish
      • Japanese (Japan)
      • Dutch
      • French
      • German
      • Chinese (Traditional Han, Taiwan)
      • Korean (South Korea)
      • Thai
      • Spanish (Chile)
      • English (United States)
      • Russian
      • Danish (Denmark)
  • Home
  • Trending

  • Login

  • Quick Links
  • Schedule A Remote Interview!
  • Check Out Our Blog
  • Buy Advertising Banners
  • Buy Pre-Roll Advertisements
  • Boost Your Earned Media starting at Just $60
  • Create A Deep Dive Conversation
  • Advertising Specifications
  • Our Editorial Process

  • Audio and Video
  • Videos
  • Audio

  • Channels
  • Browse Channels

  • Categories
  • Acute Lymphoblastic Leukemia 5573
  • Acute Myelogenous Leukemia 218
  • Bladder 95
  • Bone Metastases 4
  • Brain 77
  • Breast 433
  • Business Management 5
  • Cervical 16
  • Chronic Lymphocytic Leukemia 200
  • Chronic Myelogenous Leukemia 49
  • Colorectal 161
  • Conference Coverage 1
  • COVID-19 42
  • Gastrointestinal 175
  • General 334
  • Head and Neck 95
  • Help 3
  • Hematologic Malignancies 185
  • Hodgkin Lymphoma 31
  • Imaging 2
  • Immunotherapy 178
  • Kidney 389
  • Liver 38
  • Lung 72
  • Lymphoma 216
  • Melanoma and Skin 100
  • Multiple Myeloma 507
  • Myeloproliferative Disease 25
  • News 149
  • Non-Hodgkin Lymphoma 78
  • Non-Small Cell Lung Cancer 505
  • Other 512
  • Ovarian 64
  • Pancreatic 100
  • Patient Resources 51
  • Pediatric 6
  • Prostate 285
  • Sickle Cell 22
  • Small Cell Lung Cancer 78
  • Soft Tissue Sarcoma 12
  • Supportive Care 47
  • Testicular 3
  • Urology 16
  • Uterine 9

  • Install
  • Play a Link
  • About
  • Contact
  • Acute Lymphoblastic Leukemia 5573
  • Acute Myelogenous Leukemia 218
  • Bladder 95
  • Bone Metastases 4
  • Brain 77
  • Breast 433
  • Business Management 5
  • Cervical 16
  • Chronic Lymphocytic Leukemia 200
  • Chronic Myelogenous Leukemia 49
  • Colorectal 161
  • Conference Coverage 1
  • COVID-19 42
  • Gastrointestinal 175
  • General 334
  • Head and Neck 95
  • Help 3
  • Hematologic Malignancies 185
  • Hodgkin Lymphoma 31
  • Imaging 2
  • Immunotherapy 178
  • Kidney 389
  • Liver 38
  • Lung 72
  • Lymphoma 216
  • Melanoma and Skin 100
  • Multiple Myeloma 507
  • Myeloproliferative Disease 25
  • News 149
  • Non-Hodgkin Lymphoma 78
  • Non-Small Cell Lung Cancer 505
  • Other 512
  • Ovarian 64
  • Pancreatic 100
  • Patient Resources 51
  • Pediatric 6
  • Prostate 285
  • Sickle Cell 22
  • Small Cell Lung Cancer 78
  • Soft Tissue Sarcoma 12
  • Supportive Care 47
  • Testicular 3
  • Urology 16
  • Uterine 9
ENTRATA Study: How does it affect clinicians today? #ESMO19
0:01:56

ENTRATA Study: How does it affect clinicians today? #ESMO19

Chung-Han Lee, MD @ChungHanLee3 of @sloan_kettering answers how it affects clinicians and what is to come in kidney cancer.

_______

Data shared today in oral presentation at ESMO Congress 2019 show telaglenastat doubles median progression-free survival (PFS) in heavily pre-treated patients with advanced disease, reduced risk of death by 36% (HR=0.64, p=0.079 one-sided)

 

First glutaminase inhibitor to demonstrate clinical activity for treatment of cancer

 

SOUTH SAN FRANCISCO, Calif., Sept. 28, 2019 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other life-threatening diseases, presented today supporting data for its previously reported positive results from its randomized placebo-controlled Phase 2 ENTRATA study of telaglenastat (CB-839) in combination with everolimus in patients with advanced renal cell carcinoma (RCC). The telaglenastat-everolimus combination doubled the median progression-free survival (PFS) in heavily pre-treated patients with advanced RCC and had a well-tolerated safety profile. Telaglenastat is the first glutaminase inhibitor to demonstrate clinical activity for the treatment of cancer.

 

Calithera announced top-line results from the ENTRATA trial in June. Data from the study were accepted as a late-breaker abstract and will be shared for the first time this morning during an oral presentation at the European Society for Medical Oncology (ESMO) Congress 2019 in Barcelona, Spain (#LBA54).

 

“Outcomes for late-line metastatic renal cell carcinoma are often poor using currently available medications with similar mechanism of action,” said Chung-Han Lee, MD, PhD, Memorial Sloan Kettering Cancer Center, who will present the data. “New treatments with novel mechanisms of action are greatly needed for this patient population. The results from the randomized ENTRATA trial demonstrate activity of telaglenastat in RCC and provide proof of concept for glutaminase inhibition as a new mechanism of action that may improve outcomes for patients with this disease.”

 

“We continue to be encouraged by these data, which suggest that glutaminase inhibition – and telaglenastat in particular - could offer advanced RCC patients a novel therapeutic option,” said Susan Molineaux, PhD, president and chief executive officer of Calithera. “ENTRATA demonstrates a clinically meaningful improvement in progression-free survival among patients with advanced disease who have been treated with many prior lines of therapy. We are evaluating telaglenastat in the ongoing CANTATA trial in combination with cabozantinib for patients with advanced clear cell RCC, and we look forward to learning how telaglenastat performs in this setting.”

Read here: https://www.oncologytube.com/video/data-from-randomized-phase-2-entrata-study-demonstrate-telaglenastat-with-everolimus-improves-progression-free-survival-in-renal-cell-carcinoma

36 Views
2 years ago
Cancer
Add to
Want to watch this again later?
Sign in to add this video to a playlist. Login

Kidney

Article: Transcript: EV-301 Stats: A Cheat Sheet for Oncologists Treating Urothelial Cancer  - Jonathan E. Rosenberg, MD @DrRosenbergMSK @MSKCancerCenter @AstellasUS @Seage...
Article: Transcript: EV-301 Stats: A Cheat Sheet for Onco...
31 Views
1 month ago
Annual Meeting
Add to
Want to watch this again later?
Sign in to add this video to a playlist. Login
Podcast Richard Woodman, MD @EisaiUS #ASCO22 #OncoTwitter Phase 3 CLEAR 307 Study
0:10:05
Podcast Richard Woodman, MD @EisaiUS #ASCO22 #OncoTwitter...
9 Views
2 months ago
Annual Meeting
Add to
Want to watch this again later?
Sign in to add this video to a playlist. Login
Richard Woodman, MD @EisaiUS #ASCO22 #OncoTwitter Phase 3 CLEAR 307 Study
0:10:05
Richard Woodman, MD @EisaiUS #ASCO22 #OncoTwitter Phase 3...
18 Views
2 months ago
Annual Meeting
Add to
Want to watch this again later?
Sign in to add this video to a playlist. Login
Podcast Toni Choueiri, MD @DrChoueiri @df_hcc @DanaFarbernews #ASCO22 #OncoTwitter Phase III KEYNOTE-564 Follow-Up
0:03:32
Podcast Toni Choueiri, MD @DrChoueiri @df_hcc @DanaFarber...
2 Views
2 months ago
Annual Meeting
Add to
Want to watch this again later?
Sign in to add this video to a playlist. Login
Toni Choueiri, MD @DrChoueiri @df_hcc @DanaFarbernews #ASCO22 #OncoTwitter Phase III KEYNOTE-564 Follow-Up
0:03:32
Toni Choueiri, MD @DrChoueiri @df_hcc @DanaFarbernews #AS...
84 Views
2 months ago
Annual Meeting
Add to
Want to watch this again later?
Sign in to add this video to a playlist. Login
Podcast Laurence Albiges, MD @AlbigesL @GustaveRoussy #ASCOGU22 #GU22 #RCC Phase III CheckMate 214 Trial
0:08:54
Podcast Laurence Albiges, MD @AlbigesL @GustaveRoussy #AS...
20 Views
5 months ago
Genitourinary GU Cancer Meeting
Add to
Want to watch this again later?
Sign in to add this video to a playlist. Login
Laurence Albiges, MD @AlbigesL @GustaveRoussy #ASCOGU22 #GU22 #RCC Phase III CheckMate 214 Trial
0:08:54
Laurence Albiges, MD @AlbigesL @GustaveRoussy #ASCOGU22 #...
78 Views
5 months ago
Genitourinary GU Cancer Meeting
Add to
Want to watch this again later?
Sign in to add this video to a playlist. Login
Michael P. Bailey, CEO  AVEO Oncology
0:09:49
Michael P. Bailey, CEO AVEO Oncology
103 Views
5 months ago
Cancer News
Add to
Want to watch this again later?
Sign in to add this video to a playlist. Login
Dharmesh Gopalakrishnan, MD @DharmeshGopala1 @RoswellUrology @RoswellPark #ASCO21 #SarcomatoidRenalCellCarcinoma #Cancer #Research A Multicenter Study: ICI In Advanced sRCC
0:07:48
Dharmesh Gopalakrishnan, MD @DharmeshGopala1 @RoswellUrol...
221 Views
1 year ago
Annual Meeting
Add to
Want to watch this again later?
Sign in to add this video to a playlist. Login
Brian Rini, MD @brian_rini @VUMC_Cancer #KEYNOTE426 #ASCO21#KidneyCancer #Cancer #Research Results from 42-month follow-up of KEYNOTE-426
0:05:57
Brian Rini, MD @brian_rini @VUMC_Cancer #KEYNOTE426 #ASCO...
112 Views
1 year ago
Annual Meeting
Add to
Want to watch this again later?
Sign in to add this video to a playlist. Login
Brian Rini, MD @brian_rini @VUMC_Cancer #TIVO3 #KidneyCancer #Cancer #Research U.S. FDA Approval tivozanib for the Treatment of Adult Pts with RARCC
0:05:00
Brian Rini, MD @brian_rini @VUMC_Cancer #TIVO3 #KidneyCan...
219 Views
1 year ago
Cancer News
Add to
Want to watch this again later?
Sign in to add this video to a playlist. Login
Xiaoqiang Wang, MD @CityofHope #ProstateCancer #Cancer #Research White Button Mushrooms Could Slow Progression Of Prostate Cancer
0:05:39
Xiaoqiang Wang, MD @CityofHope #ProstateCancer #Cancer #R...
74 Views
1 year ago
Cancer News
Add to
Want to watch this again later?
Sign in to add this video to a playlist. Login

Copyright 2022 Medicus Networks, Inc. 45121 Morgan Heights Rd. Temecula, CA 92592